Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 12 Dec 2024 for Pieris Pharmaceuticals, INC., €0. Read the official filing
Filing timeline
BuySaleJames A. Geraghty
Insider track record
Disclosed buys
2
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+177.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
James A. Geraghty: trading record in brief
This profile gathers the share dealings of James A. Geraghty across 3 companies, led by Palvella Therapeutics, Inc., Fulcrum Therapeutics, Inc. and Orchard Therapeutics plc. The record holds 4 filings, for trades running from 28 June 2021 to 12 December 2024.
Purchases make up the whole of the open-market record (2 purchases, €77k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2024 alone, the filings show 1 purchase and no sales.
On 12 December 2024 came the latest disclosure, a transaction for €0 in Palvella Therapeutics, Inc. The last purchase on record was published on 28 October 2024, which is 721 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to James A. Geraghty
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
1 shares@ US$0.011.0% of flowSeries F Preferred Stock, par value $0.001 per shareSEC:0001437749-24-037353:0
1 shares@ US$1.0099.0% of flowSeries F Preferred Stock, par value $0.001 per shareSEC:0001437749-24-032319:0
Canonical exit: 5 Nov 2024 (T+90)
44,391 sharesOrdinary SharesSEC:0000950170-24-007087:0
10,000 shares@ US$9.16100.0% of flowCommon StockSEC:0000899243-21-026552:0
Canonical exit: 26 Sept 2021 (T+90)
4 of 4 declarations
